While TLR3 activation can stimulate acute inflammation that potentially enhances anti-tumor immunity by activating dendritic cells and effector T-cells, chronic or dysregulated inflammation, a hallmark of many cancers, fosters an immunosuppressive tumor microenvironment that supports tumor progression, metastasis, and therapy resistance [48, 49]. The gene discussed is TLR3; the disease is neoplasm.